A
Ai Therapeutics
AI Therapeutics - Deep Learning Precision Medicine
About Ai Therapeutics
OrphAI Therapeutics, formerly known as AI Therapeutics, is a clinical-stage biopharmaceutical company dedicated to developing treatments for rare diseases. The company leverages artificial intelligence to identify and advance a pipeline of drug candidates, with a particular focus on conditions with high unmet medical needs.
Read full description
OrphAI's portfolio includes multiple programs in Phase 2 clinical trials. One of its key candidates, AIT-101, has received Orphan Drug Designation for the treatment of specific disorders. The company is also actively involved in developing therapies for rare pediatric cancers. OrphAI's business model centers on the discovery, development, and subsequent commercialization of novel therapeutics for orphan diseases, a market segment with significant growth potential due to the specialized nature of the treatments and the often-limited competition.
At a glance
- Founded
- 2013
- Headquarters
- Guilford, United States
- Sector
- Biotech & Life Sciences
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later1 investor entered at this stage
Yuansheng BioVenture
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Ai Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Ai Therapeutics on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.